References
- Atkinson MA. Thirty years of investigating the autoimmunebasis for type 1 diabetes. Diabetes. 2005;54:1253–1263.
- Baynes HW. Classification, Pathophysiology, Diagnosis and Management of Diabetes Mellitus. J Diabetes Metab. 2015;6:541.
- American Diabetes Association. Diabetes 2001 Vital statistics.Alexandra. VA: ADA; 2010.
- International Diabetes Federation. IDF Diabetes Atlas. 2015. 7th edn. Available from: www.diabetesatlas.org
- Maahs DM, West NA, Lawrence JM, et al. Epidemiology of type 1diabetes. Endocrinol Metab Clin North Am. 2010;39:481–497.
- Weng J, Zhou Z, Guo L, et al. T1D China Study Group. Incidence of type 1 diabetes in China, 2010–13: population based study. BMJ. 2018;360:j5295.
- Rogers MAM, Kim C, Banerjee T, et al. Fluctuations in the incidence of type 1 diabetes in the United States from 2001 to 2015: a longitudinal study. BMC Med. 2017;15:199.
- Thomas NJ, Jones SE, Weedon MN, et al. Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes Endocrinol. 2018;6:122–129.
- Palmer JP, Hampe CS, Chiu H, et al. Is latent autoimmune diabetes in adults distinctfrom type 1 diabetes or just type 1 diabetes at an older age? Diabetes. 2005;54:62–67.
- Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature. 2010;464:1293–1300.
- Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750–754.
- Raju SM, Raju B. Illustrated medical biochemistry. 2nd ed. New Delhi, India: Jaypee Brothers Medical Publishers ltd; 2010. p. 645.
- Siddique AA, Siddiqui AS, Ahmad S, et al. Diabetes: mechanism, pathophysiology and management. Int J Drug Dev Res. 2013;5:1–23.
- Figueiredo LF, Schuster S, Kaleta C, et al. Cansugars be produced from fatty acids? A test case forpathway analysis tools. Bioinformatics. 2009;25:152–158.
- Srivastasan R, Gadde R, Manoj-kumar K, et al. Antioxidants and lipids peroxidation status in diabetic patient with and without complication. Arch Iran Med. 2007;12:121–127.
- Rains JL, Jain SK. Oxidative stress, insulin signaling, anddiabetes. Free Radic Biol Med. 2011;50:567–575.
- Peerapatdit T, Likidlilid A, Patchnans N, et al. Antioxidant status and lipid peroxidation end products in patients of Type 1 Diabetes mellitus. J Med Assoc Thai. 2006;89:141–146.
- Sena MC, Bento CF, Pereira P. Diabetes mellitus: challengesand innovative therapies. Epma J. 2010;1:138–163.
- Corathers SD, Peavie S, Salehi M. Complications of Diabetes Therapy. Endocrinol Metab Clin North Am. 2013;42(4):947–970.
- Morales A. A better future for children with type 1 diabetes: reviewof the conclusions from the diabetes control andcomplications trial and the epidemiology of diabetes interventions and complications study. J Ark Med Soc. 2009;106:90–93.
- Rezaei A, Farzadfard A, Amirahmadi A, et al. Diabetes mellitus and its management with medicinal plants: A perspective based on Iranian research. J Ethnopharmacol. 2015;175:567–616.
- Furth ME, Atala A. Stem cell sources to treat diabetes. J Cell Biochem. 2009;106:507–511.
- Bamisaye FA, Odutuga AA, Minari JB, et al. Evaluation of hypoglycemic and toxicological effects ofleaf extracts of Morinda lucida in hyperglycemic albinorats. Int Res J Biochem Bioinf. 2013;3:37–43.
- Adeneye AA, Olagunju JA, Olatunji BH, et al. Modulatory effect of morinda lucida aqeous stem bark extract on blood glucose and lipid profile in Alloxan induced diabetic rats. Afr.j.Biomed.Res. 2017;20:75–84.
- Adeneye AA, Agbaje EO. Pharmacological evaluationof oral hypoglycemic and antidiabetic effects of fresh leavesethanol extract of Morinda lucida benth. In normal and alloxaninduced diabetic rats. Afr.j.Biomed.Res. 2008;11:65–71.
- Ojewunmi O, Oshodi T, Ogundele O, et al. Evaluation of the antidiabetic and antioxidant activities of aqueous extracts of Morinda lucida and Saccharum officinarum leaves in alloxan-induced diabetic rats. Int J Biochem Res Rev. 2013;3:266–277.
- Chougale AD, Shrimant P, Gurao PM, et al. Optimization of Alloxan dose is essential to induce stable diabetes for prolonged period. Asian J Biochem. 2007;2:402–408.
- Friedewald WT, Levy RI, Fredrickson DS. Estimationof the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparativeultracentrifuge. Clin Chem. 1972;18:499–502.
- Michael OS, Olatunji LA. Ameliorative effect ofnicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthasekinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy. Arch Physiol Biochem. 2017. DOI:10.1080/13813455.2017.1369549
- Etuk EU. Animal models for studyingdiabetes mellitus. Agric Biol J North Am. 2010;1:130–134.
- Viana GS, Medeiros AC, Lacerda AM, et al. Hypoglycemic and anti-lipemic effects ofthe aqueous extract from Cissus sicyoides. BMC Pharmacol. 2004;8:4–9.
- Rohilla A, Ali S. Alloxan induced diabetes: mechanismand effect. IJRPBS. 2012; 3:2229–3701.
- Siddique AA, Siddiqui AS, Ahmad S, et al. Diabetes: mechanism, pathophysiology and management. Int J Drug Dev Res. 2013;5:1–23.
- Atanu FO, Momoh S. Amelioration of histological changes and associated metabolic abnormalities by a combination of Morinda lucida and metformin in diabetic rat. J Phytopharmacol. 2018;7:253–256.
- Dokken DB, Tsao T. The physiology of body weight regulation: arewe too efficient for our own good? Diabetic Spectr. 2007;20:166–170.
- Dobiasova M, Frohlichb J. The plasma parameter log (TG/HDL-C) as an Atherogenic index: correlation with lipoprotein particle size and esterification rate in apob Lipoprotein depleted plasma. Clin Biochem. 2001;34:583–658.
- Davidson MH. Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C andeach of five other emerging risk factors for coronary heart disease: non–HDL-cholesterol,TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. Clin Lipidol. 2008;2:436–446.
- Jarvisalo MJ, Jartti L, Nanto-Salonen K, et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation. 2001;104:2943–2947.
- Chen H, Li X, Epstein PN. MnSOD and catalase transgenes demonstrate that protection of islets from oxidative stress does not alter cytokine toxicity. Diabetes. 2005;54:1437–1446.
- Lepore DA, Shinkel TA, Fisicaro N, et al. Enhanced expression of glutathione peroxidase protects islet beta cells from hypoxia-reoxygenation. Xenotransplantation. 2004;11:53–59.
- Hurrle S, Hsu WH. The etiology of oxidative stress in insulin resistance. Bio Med J. 2017;40:257–262.
- Kantoosh MM, Naiem A, El- Sayad M, et al. Dyslipidemia and lipid peroxidation in type 1 Diabetic children with good glycemic control: response to antioxidant therapy. Alex J Pediatr. 2002;16:357–364.
- Adejo GO, Atawodi SE, Ameh DA, et al. Anti-peroxidant, protective and ameliorative properties of methanol extract of all part of morinda lucida benth in CC14-induced liver injury. Nat Prod Chem Res. 2014;2:S1–003.